Professor A. Loubatieres (Montpellier, France)': Experimental Studies for the Tentative Use of Hypoglycwmic Sulphonamides as Prophylactic Agents against Diabetes It is now well established that hypoglycemic sulphonamides, whether thiodiazole or urea derivatives, have the same mechanism of action. They have a particular influence on the beta cells of the islets of Langerhans and are inactive after total extirpation of the pancreas. A small fragment of normal pancreas (including normal islets) representing one-tenth of the initial pancreatic gland is, however, sufficient to maintain their hypoglyceemic activity (Loubatieres, 1944 (Loubatieres, , 1946a .
The administration of sulphonamide to a normal animal induces a clear-cut degranulation of the beta cells of the islets of Langerhans (Gepts et al., 1955 (Gepts et al., , 1956 Creutzfeldt and Finter, 1956; Volk et al., 1956; Holt et al., 1956; Loubatieres, 1957c; Loubatieres, Sassine, Fruteau de Laclos and Bouyard, 1957; Loubatieres and Fruteau de Laclos, 1958; Kracht, 1958; Fruteau de Laclos and Loubatieres, 1960) which suggests 'Present address: Professor of Applied Physiology and Pharmacodynamics, Faculty of Medicine of Montpellier, Institute of Biology, Armand Gautier Street, Montpellier, France. AUGUST that some intraprotoplasmic insulin particles have been liberated into the circulating blood. Lacy and Hartroft (1959) have shown, with the electron microscope, that the administration of tolbutamide is followed by the loss of insulin granules from the beta cells. The degranulation is a functional one; it is reversible and within a few hours the insulin granules re-form in normal numbers (Pfeiffer et al., 1957) . These phenomena are seen most strikingly in the cells close to blood vessels. Hypoglycmmic sulphonamides administered to certain animals (the rat, rabbit, dog and mouse) for several days induce hyperplasia of the islets of Langerhans and new formation of the insulin secretory beta cells (Loubatieres, 1946b; Ashworth and Haist, 1956; Gepts et al., 1956; Kracht, 1958) . This hyperplasia is due in part to mitotic division of the existing beta cells, as can be shown by the use of colchicine (Kracht, 1958; Jores and Kracht, 1959) , and in part, as we have found, to small islets developing in the acinar tissue (Loubatieres and Fruteau de Laclos, 1958; Fruteau de Laclos and Loubatieres, 1960) .
These newly formed beta cells appear next to and probably have their origin from the centroacinar cells and from the cells of certain of the excretory canaliculi. Intermediate forms be-Sectional page 27
Vol. 53 595 tween acinar cells and endocrine cells are visible (Loubati&res and Fruteau de Laclos, 1958;  Fruteau de Laclos and Loubatieres, 1960) . From these cellular transformations it follows that the total amount of beta cell tissue increases (Ashworth and Haist, 1956) and thus the effectiveness of the endocrine tissue in the regulation of the blood sugar level becomes greater. The phenomenon of hypoglycemia and islet hyperplasia, particularly the new formation of beta cells, is especially striking if the sulphonamide is administered through the Wirsung duct of the pancreas (Loubatieres, Sassine, Mariani and Fruteau de Laclos, 1960) . By pancreatico-jugular anastomosis or crosscirculation between a donor dog treated with sulphonamide and a recipient dog receiving the pancreatic blood of the donor, it is possible to show the passage, from donor to recipient dog, of the excess insulin secreted into the blood by the pancreas of the animal treated with sulphonamide. When pancreatico-duodenal venous blood of a normal dog is transfused to a responsive recipient dog, it is more hypoglyc=mically active after the administration of sulphonamide than before (Loubatieres, 1946a; Loubatieres, Bouyard and Sassine, 1958) .
In addition to their action on the beta cells the hypoglycemic sulphonamides reinforce the effects of exogenous or endogenous insulin on blood glucose (Loubatieres, Bouyard, Fruteau de Laclos, Sassine and Alric, 1956; Loubatieres, Bouyard, Sassine and Fruteau de Laclos, 1957; Houssay and Migliorini, 1956 )-an effect which can be observed in the totally depancreatized animal.
Different hypotheses have been proposed to explain this phenomenon, notably the theory of insulinase inhibition (Mirsky et al., 1956) , but most authors have now discarded this. We think that potentiation of insulin, which is only observed with large doses of sulphonamide, can be explained by the liberation of insulin, previously injected or secreted, that has been fixed to certain proteins. These molecules of liberated insulin may exert their activity in situ or be returned to the circulation and thus become capable of exhibiting elsewhere their normal activity. Such a process of liberation of fixed insulin might be similar to the action of sulphonamides on the beta cell granules because the latter are probably complexes of insulin and protein (Loubatieres, 1959b) .
The hypoglycxmic action of the sulphonamides just described is only one aspect of their mechanism of action. These substances also possess an "anti-diabetic action" (Loubatieres, 1946b (Loubatieres, , 1955 (Loubatieres, , 1957a . By this we mean that hypoglycxmic sulphonamides can, in some conditions, reduce the fundamental cause of the diabetic state, which seems to depend upon a numerical and functional deficiency of beta cells, and in other conditions prevent the development of the diabetic state. There follows a significant rectification of the metabolic abnormalities and a tendency towards normality of the regulation of the blood sugar level.
What are the effects of prolonged treatment with sulphonamides on the dog suffering from meta-alloxan diabetes? (Loubatieres, 1955; Loubatieres, Bouyard and Fruteau de Laclos, 1955, 1956; Loubatieres, Bouyard, Fruteau de Laclos and Sassine, 1957; Loubatieres, 1957a, b; Loubatieres, Bouyard, Sassine and Fruteau de Laclos, 1958.) If the diabetes is initially severe the dog may lose weight, develop ketosis and eventually die. Treatment with sulphonamide appears unable to alter this sequence. During the course of the experiment, successive pancreatic biopsies show that islets of Langerhans which had been seriously damaged before treatment with sulphonamide remain so after treatment. The beta cells are largely destroyed and are often replaced by scar tissue. The very few beta cells which escape destruction by alloxan are degranulated. No process of new formation of islet cells is seen, probably because those mother cells which might have provided the source of new beta cells have themselves been destroyed. Even if some of these survive, they will quickly be exhausted and finally damaged by their struggle against the high blood sugar which the sulphonamide is not able to reduce. The cycle maintaining the diabetic state has been set in motion and the sulphonamides cannot break it.
However, carefully controlled insulin therapy, associated with sulphonamide treatment, may enable the sulphonamide to exert its trophic action on the islets of Langerhans. The dosage of insulin can then be progressively reduced by 50-80 %. In such instances a histological examination of the pancreas reveals new beta cells. These newly formed cells originate particularly from the cells of the excretory canaliculi and probably from the acinar tissue. However, endocrine tissue is fragile and not well developed. Perhaps, in such instances, the exogenous insulin comes to the aid of the sulphonamides and of the endocrine tissue of the pancreas.
On the other hand if the diabetes is of only moderate severity its development will generally be different. Treatment with sulphonamide alone during a period of some weeks can lead to a reduction of the diabetic symptoms and even to their disappearance (Loubatieres, 1955; Loubatieres, Bouyard and Fruteau de Laclos, 1955, 1956; Loubat eres, 1957a, b, c; Loubatieres, Bouyard, Sassine and Fruteau de Laclos, 1958) . The benefit is well shown by a rapid increase in the body weight of the animal which, before treatment with sulphonamide, tended to fall. At the *end of three to eight weeks, treatment can be stopped and the animal may remain "cured". In such cases histological examination of the pancreas shows changes comparable with those induced by hypoglycemic sulphonamides in the normal animal. Their development and intensity are, however, of lesser degree.
New beta cells appear, originating from the cells of the external secretory canaliculi and the centro-acinar cells, which become clearly identifiable and globular. Transitional forms between exocrine and endocrine cells are also visible; many small islets of Langerhans appear. Pancreatic ductules are dilated. Only if the "cure" is maintained do the islets of Langerhans develop and become well organized. The cellular reorganization of pancreatic tissue characteristic of the action of sulphonamides can therefore occur (Loubatieres, Bouyard, Sassine and Fruteau de Laclos, 1958; Loubatieres and Fruteau de Laclos, 1958; Fruteau de Laclos and Loubatieres, 1960) . These substances are most effective if treatment is undertaken early during the development of the diabetic condition.
The results of the previous existence of the meta-alloxan diabetes may nevertheless be seen in the sugar tolerance curve even when "cure" has been effected (at least at the beginning of the period of "cure"). If, however, a balanced food intake (horse-meat) is permitted, such as will maintain but not increase the body weight, the sugar tolerance curve becomes lower and lower, and finally approaches normal. The process of "cure"1, which has been fostered by treatment with the sulphonamide, can continue after cessation of this treatment.
Unrestricted food intake can, by contrast, induce an increase in the body weight and threaten the state of "cure" (Loubatieres, 1958 (Loubatieres, , 1959c . This has an important bearing on the treatment of the human diabetic.
We have found that the "new equilibrium" instituted by the sulphonamide treatment rests on the formation of islet beta cells which can function. These new beta cells are normal and not unduly sensitive to the action of the mechanisms which regulate the blood sugar level. In fact, the fasting blood sugar of these animals is normal (85-90 mg/100 ml). The new beta cells can be stimulated by the same dosage of hypoglycemic sulphonamides as normal cells, since the administration of these substances induces a striking hypoglycaemia. Furthermore, these cells can be destroyed by alloxan, thus rendering diabetic once more the animal whose previous diabetes had been cured by sulphonamide treatment (Loubatieres, Bouyard, Sassine and Fruteau de Laclos, 1958) . This process of "cure" or disappearance of the diabetic symptoms, fostered and induced by sulphonamides, is not confined to meta-alloxan diabetes. It has been observed in cats with metahypophyseal diabetes (Young, 1956) .
In more recent experiments, Young et al. (1959) have produced a "cure" with tolbutamide or carbutamide in six cats with meta-hypophyseal diabetes fifteen to thirty-five weeks after stopping the injections of growth hormone. In the electron micrographs taken by J. D. Lever of some of their tolbutamide-treated cats, there was clear cytological evidence of a complete restoration of previously altered beta cells (Lever and Jeacock, 1960) .
Another example of the possibilities of "cure" of diabetes with the use of hypoglycaemic sulphonamides is given by spontaneous diabetes in the dog. Brion and Fontaine (1959) studied thd action of carbutamide in 30 cases of spontaneous canine diabetes. They concluded that the hypoglycwmic sulphonamides are inactive in advanced diabetes with ketosis and weight loss, which corresponds to the severe and neglected diabetes of the old dog. On the other hand, during the first months of induction of diabetes, when hyperglycemia is moderately increased, the administration of sulphonamide considerably reduces the diabetic symptoms. The authors conclude: "It is surprising indeed that this amelioration is often a long-lasting one. We possess now the observation of a female dog which is still in a normal state, one year after a ten-day treatment with sulphonamide compounds. More often, relapses occurred within one to two months, but could again be reversed by administration of carbutamide."
One may now ask if the regenerative action, exerted by sulphonamides on the beta cells could not be used as a tool in the prophylactic treatment of experimental diabetes. The adiministration of sulphonamide during the period of induction of diabetes (idio-hypophyseal diabetes) seems to oppose the establishment of meta-hypophyseal diabetes-the diabetic condition which occurs in the dog as the result of the administration over a three weeks' period of crude extract of anterior pituitary gland (Loubatieres, Bouyard, Fruteau de Laclos and Sassine, 1956) . Recently, Mirsky et al. (1959) administered purified anterior pituitary growth hormone to a dog simultaneously with tolbutamide, and obtained similar results. They found that the diabetogenic effect of daily intramuscular injections of somatotrophin is decreased or inhibited by the concomitant oral administration of tolbutamide. It is probable that a rise in the rate of insulin secretion and an increase in the number of beta cells capable of secreting insulin are concerned in this protective mechanism exerted by the sulphonamides against the development of meta-hypophyseal diabetes.
Recently we have attempted to investigate the possibility of a preventive action of hypoglycemic sulphonamides against the exhaustive and degenerative process which "spontaneously" occurs in the pancreatic remnant of a subtotally pancreatectomized animal (Loubatieres, Fruteau de Laclos, Mariani and Sassine, 1960; Loubatieres, Mariani, Fruteau de Laclos and Sassine, 1960) . It is well known that the maintenance of about one-tenth of the initial pancreatic gland is able to prevent, for a time, the development of diabetic symptoms. In our experiments dogs, male and female, were operated on and a pancreatic remnant of about one-tenth of the initial gland was left in situ around the proximal part of Wirsung's duct. Then, a glucose tolerance test (1 g/kg glucose orally) and a sulphonamide test (25 mg/kg chlorpropamide orally) were performed separately every fifteen days under standard conditions. Between the test days, each animal received a meat diet (15 g of raw horse-meat per kg of body weight twice a day) and 25 mg/kg of chlorpropamide. Chlorpropamide was chosen because of its long-lasting action.
So far, although receiving sulphonamide for ten months, the animals are not diabetics and their glucose tolerance tests are not higher nor more prolonged than before sulphonamide treatment. In fasting conditions their blood sugar was below the normal level. After normal meals it did not exceed 100 mg/100 ml. In the majority of glucose tolerance tests a deep hypoglycemic trough followed the hyperglycxmic period. In fact, we noticed that the glucose curves were better if sulphonamide was stopped forty-eight hours before the test; a possible explanation of the phenomenon is that sulphonamide treatment relatively reduced insulin reserves already contained in the beta cells.
Our work is still in progress and it is not yet possible to conclude that sulphonamides have a definitive protective action on the beta. cells although we are inclined to think so. It is probable that the regenerative and neoformative processes as well as the protective action that sulphonamides exert on the beta cells are largely responsible for the phenomenon we have been describing. This is in agreement with histological studies of pancreatic remnant biopsies.
We must emphasize that maintenance of functionally intact exocrine tissue is necessary for its demonstration (Loubatieres, Fruteau de Laclos, Mariani and Sassine, 1960) . For example, in the dog the formation of new beta cells, as well as the action of sulphonamides on the insulin-secreting process itself, is largely jeopardized by the progressive sclerosis in the pancreatic graft transplanted to the wall of the abdomen, although circulation in the graft is maintained through its vascular pedicle. It is possible, also, that the hypoglycwemic action of sulphonamides favours the new formation and regenerative action these substances exert on the beta cells. It is evident that the electron microscope will be'an important aid to progress in this type of investigation.
We must now ask if this "curative" or "preventive" action of sulphonamides occurs in human diabetes. In certain elderly diabetic subjects, with mild diabetes, it is sometimes possible to observe, after suspension of sulphonamide treatment, a blood-sugar level which is relatively satisfactory and which can be maintained for several weeks or months. After this period of "long-lasting" remission, the bloodsugar level tends to rise progressively and finally the full diabetic condition returns (see Loubatieres, 1958 Loubatieres, , 1959c Bloom, 1959) . It must be emphasized, however, that the better the diet is balanced and the more strictly it is followed the longer will equilibrium be maintained, and the longer the remission. A diabetic relapse is probably due to the exhaustion of new beta cells or to the progressive impairment of their membrane permeability to blood glucose on the one hand or to endogenous insulin on the other.
In certain young diabetics, with an undoubtedly familial trait of diabetes, but whose diabetes is of recent origin and has not yet resulted in a loss of body weight, treatment with sulphonamide can cause the diabetic symptoms to disappear at least for a time. Whatever the explanation, this phenomenon is important and has been observed by many authors, e.g. Larsson (1959) , Otto and Mai (1959) .
If we admit that hypoglycemic sulphonamides are able to provoke or to prolong a remission in the evolution of diabetes, could not these drugs be used as preventive or arresting agents in the course of diabetes? This problem, which I had suggested in 1958 (Loubatieres, 1958b, d) , was recently investigated during prolonged experiments (up to twenty-two months) by Fajans and Conn (1960) . They studied the effects of sulphonylurea therapy on carbohydrate tolerance of young, non-obese patients with mild, asymptomatic diabetes mellitus, and concluded that (I quote): "(1) Carbohydrate tolerance improved or became normal in thirteen of fourteen young, non-obese, mild diabetic patients during treatment with tolbutamide over a period of two to twenty-two months.
(2) Normalization of the response to a glucose load as well as occurrence of fasting and postprandial hypoglycemia suggest increased insulin secretion as a mode of action of tolbutamide in these patients. (3) The studies reported could have important bearing on the problem of prevention of diabetes mellitus."
More extensive studies are needed to determine whether prolonged treatment with hypoglycemic sulphonamides can prevent or reduce numerical or functional decompensation of insulin-secreting cells in man as well as in animals. Many authors, notably Gepts (1959) , have observed signs of beta cell regeneration and islet hyperplasia in the pancreas of patients submitted to prolonged treatment with sulphonamides.
It is particularly desirable that experiments of the type done by Fajans and Conn should be expanded both in the numbers of patients and in the duration of the observation. Success will depend upon strict control of treatment and diet and careful selection of patients in the early stage of diabetes. (1955) C.R. Acad. Sci., Paris, 241, 515.
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Dr. John Malins (Birmingham):
It is generally agreed that the sulphonylureas are effective in lowering the blood sugar of some diabetic subjects, that this is an insulin effect and that tolbutamide and chlorpropamide are safe enough to be used in general practice, the side-effects being minimal if the correct dosage is adhered to. With all the sulphonylureas, the effective dose varies little from patient to patient, and if an adequate blood level of the drug is achieved, but without clinical response, nothing is gained by increasing the dose. At the General Hospital, Birmingham, 1,129 patients have received oral treatment-72 with carbutamide, 753 with tolbutamide and 304 with chlorpropamide, which, because of its prolonged action and powerful effect, is now the drug of choice. The combination of sulphonylurea with insulin was abandoned as there was no evidence that it improved control. The diguanides with their unphysiological mode of action are not as yet considered safe for general use.
Oral treatment is considered: (1) In newly diagnosed cases thought unlikely to respond to diet; or when a symptom such as pruritus vulve is so severe that rapid removal of glycosuria is essential.
(2) When diet has failed either to control symptoms or to keep the blood sugar within the normal range. These patients are often obese and lack the will powers to lose weight. It is necessary to decide whether obesity or uncontrolled diabetes is the greater threat to life. If prolonged efforts at dieting have failed (and every patient should have the principles of dieting carefully explained) it is best to treat the hyperglycemia as such. Patients with a persistently raised blood sugar run an increased risk of complications either acute, such as neuropathy, or chronic and vascular. (3) Those receiving insulin, but whose lives do not seem to depend on it, are considered for oral treatment, particularly if hypoglycwmia is troublesome; hypoglycemia is the greatest disadvantage of insulin treatment. All patients under the age of 40 and all those who take more than 30 units of insulin daily may be excluded as only a minority in these groups would respond, but the exceptions can be important, e.g. men who have to change their work if put on insulin, and elderly patients living alone. Conversely oral treatment is not always satisfactory for these patients, because they may forget or neglect to take tablets.
To evaluate oral treatment in clinical practice 468 cases of newly diagnosed diabetes who attended in 1958 have been analysed. Table I shows the initial treatment and the results at the end of one year. "Satisfactory" denotes a com-plete response with a normal blood sugar one hour after a meal. "Partial" denotes relief of symptoms with a blood sugar below 250 mg/100 ml, and "Failure" the persistence of symptoms with a blood sugar above 250 mg/100 ml. Apart from those cases considered mild enough for diet only or severe enough to need immediate insulin therapy, all patients were eligible for oral treatment regardless of age, blood sugar or moderate ketoniiria. Two patients were controlled perfectly throughout pregnancy with delivery of healthy infants at the 37th week. Table II shows the results of oral treatment at the end of one year related to age, body weight, and the initial blood sugar. 24% 16%
It appears that a good response is most likely in those over the age of 40, those who are obese and those with an initial blood sugar below 300 mg/100 ml, but is by no means rare in the other groups. Our experience confirms that of Mehnert et al. (1958) , that oral treatment is more successful in men than women, in the older patient, and in those with a shorter history of previous treatment, low insulin requirements and short duration of insulin treatment. But these are generalizations and it is worth emphasizing once more that the exceptions form a significant group and one in which a good result may be especially desirable. The hypoglycemic sulphonamide derivatives have been shown to control diabetes in some middle-aged patients, but the development of "acquired resistance" is a source of anxiety. At the Middlesex Hospital Diabetic Clinic 107 patients responded satisfactorily to tolbutamide when they were started on this form of treatment between two and four years ago. At the present time only 27 remain satisfactorily controlled by the drug, 35 have developed "'acquired resistance", 10 have been taken off it on account of sideeffects (rashes in 3 and abdominal pain in 7), and 10 because they were putting on too much weight. The time of development of the acquired resistance is shown in Table 1 .
The rate of development of resistance is approximately 2% of patients on treatment per month; this may be compared to the figure of 3% per month given by DeLawter et al. (1959) . Chlorpropamide has now been on trial for about two years. It is more potent as a hypoglycmmic agent, partly because excretion is slower and the blood levels are higher but in addition it seems to have a greater effect than tolbutamide at the same blood level (Stowers et al., 1959) . The increased potency is shown in Tolbutamide treatment two years. day tolbutamide after two years' treatment. When this drug was stopped the blood sugar rose by 100 mg/100 ml. Chlorpropamide treatment was started and after some adjustment of the dose satisfactory control was obtained with 0 5 g/day with reduction of blood sugar by 200 mg/100 ml. The patient has now remained well controlled on chlorpropamide for twelve months.
The results of giving chlorpropamide to patients with acquired resistance to tolbutamide confirm that it is a more potent hypoglycemic agent. Of 25 patients so treated, .15 have been well controlled for periods of up to eighteen months, 7 failed to respond and 3 after an initial response have developed acquired resistance to chlorpropamide. k When chlorpropamide was first introduced the doses used were excessive, and troublesome side-effects like drowsiness, confusion and ataxy were noted (Murray et al., 1958) . A number of patients developed cholangiolitic hepatitis (Brown et al., 1959) . These complications are unusual with the dose currently employed. We have given chlorpropamide to 95 patients, and the doses used for maintenance therapy have been from 100 to 500 mg/day. Side-effects noted have been mild abdominal discomfort (2 patients) and in 2 others skin rashes have necessitated stopping treatment. One patient has had hypoglycamic attacks. Acquired resistance to chlorpropamide has developed in 6 patients: 3 transferred from tolbutamide, having become resistant to that drug, became resistant to chlorpropamide after six to eleven months' treatment and 3 treated only with chlorproXpamide developed resistance after eight to fifteen months. These 6 cases of acquired resistance have developed in a group of 81 giving an initial satisfactory response; at a comparable stage in our tolbutamide trial the incidence was 12 out of 79.
Patients who have failed to respond to chlorpropamide or who have become resistant to its action are now being given small doses of diguanides in addition. Of 6 primary failures, 4 have responded to this combination of hypoglyc'emic agents. 3 cases of acquired resistance have been given phenformin or metformin with the chlorpropamide and all are at present satisfactorily controlled. Dr. R. S. Walker (Glasgow): Phenethyldiguanide (D.B.I.) Phenethyldiguanide (D.B.I.) is a potent hypoglycemic drug, whether or not there is an intrinsic source of insulin: accordingly it has been claimed to have a place in the treatment of all types of diabetes (Steiner and Williams, 1959; Pomeranze et al., 1959) . This paper is a report of our experiences with 109 patients in two years. The cases were selected only on their need for inception of therapy or alteration of existing treatment and on their ability to cooperate.
The patients were divided, before treatment began, into four somewhat arbitrary groups:
(1) Adult (stable): Appearing after 40 without initial ketonuria. Low insulin dose <40 units.
(2) Juvenile (unstable): Acute onset, ketonuria.
(3) Stable juvenile: No history of ketosis. Low insulin dosage, slow onset. (4) Unstable adult: Acute onset with ketosis, age over 40.
The grouping of the 109 patients and the success rates in the various groups are shown in Table I . Partial success indicates that the insulin dose was less than two-thirds of the initial one and control was better as measured by blood-sugar levels and absence of hypoglycaemia.
The third and fourth groups behave like the major divisions. The adult unstable resembled the juvenile unstable, and the two stable groups were similar.
The success rate of adult cases was further analysed in relation to previous therapy: dietary cases, 83 % success; previous insulin therapy, 22% success; failed oral drug, 66% success.
The successes were for a mean of 154 months. The appearance of secondary failures was unusual but did occur. Hom-ever, the drug compares favourably with the sulphonylureas in the new adult case.
The causes of early and late failure are shown in Table II . Nausea rarely led to failure when the drug was only increased slowly; in adults it appeared later in 6 cases after an average of almost six months. Secondary or late failure of hypoglycxmic effect occurred in the three larger groups, and was more frequent in the insulin-dependent. Ketosis occurred fairly frequently, sometimes with normoglycimia, and the drug had to be withdrawn (Hall et al., 1958) . Primary failure of hypoglycxmic effect occurred fairly often in insulin-dependent patients, but did not occur in a "new" case. Examples of secondary failure were: (1) An adult who had twelve months' good control of blood sugar after which the levels were unaltered by increased dosage. (2) A juvenile case, controlled well for fifteen months and previously reported, I think justifiably, as a success. She later failed, in spite of increased dose. When supplementary insulin control was established and the drug withdrawn, no effect was noted on the insulin requirement. (3) A juvenile case temporarily well controlled but the hypoglycemic effect failed after four months. Reintroduction of D.B.I. had no effect on insulin needs.
The appearance of acetonuria with normal or mildly elevated blood sugars has caused us much anxiety. This is a phenomenon peculiar, so far as we know, to this drug. It has been associated with very low alkali reserve and in 2 cases the levels were 3 0 and 4 9 mEq/l. with blood sugars of 270 and 210 mg/100 ml (Walker and Linton, 1959) . The former patient died, although on a supplement of 12 units of insulin, after nine months of adequate control. These two were extreme examples of a trend we encountered often. Of 35 who showed ketonuria, only 9 were adult. Of the 11 severely acidotic, as measured from the alkali reserve, only 1 was an apparently stable adult.
The keto-acidosis picture appeared more often after sustained exercise and for this reason we tried exposing normals, diabetics on insulin and diabetics on D.B.I. to standard exercise. Lactic acid levels were estimated immediately and fifteen minutes later; the results indicate that these are severely disturbed (see Fig. 1 ).
Moreover, many resting blood lactate levels were considerably elevated. This we regard as evidence that in the unstable and presumably insulin-dependent diabetic, a disturbance of scarbohydrate metabolism exists so that lactate disposal is impaired or excess production occurs (Moorhouse et al., 1958) . As several of these patients were on supplementary insulin, it is possible that D.B.I. can alter its action. The patients were under the care of Dr. A. C. Aitkenhead; Dr. W. S. T. Thompson, Dr. A. L. Linton and Dr. R. Hannah have assisted in much of this work.
